|
1
|
Scott DW and Gascoyne RD: The tumour
microenvironment in B cell lymphomas. Nat Rev Cancer. 14:517–534.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marcus EBR, Sweetenham JW and Williams ME:
Pathology, diagnosis and treatment. Cambridge University Press;
2013, View Article : Google Scholar
|
|
3
|
Kuna T, John O, Kobler P and Filipovićzore
I: A finding of diffuse cellular non-Hodgkin lymphoma in the oral
cavity-case presentation Dg: Diffuse giant cell Non-Hodgkin
lymphoma B-immunophenotype. Acta Stomatol Croatica. 38:2792004.
|
|
4
|
Bardia A and Seifter E: Johns Hopkins
Patients' Guide to Lymphoma. Shockney L and Shapiro GR: Jones and
Bartlett; Sudbury, MA, USA: 2011
|
|
5
|
Armitage JO, Gascoyne RD, Lunning MA and
Cavalli F: Non-Hodgkin lymphoma. Lancet. 390:298–310. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Surveillance E and Program ER: SEER stat
fact sheets: Non-Hodgkin Lymphoma. 2014.
|
|
7
|
Stewart BW and Wild CP: World Cancer
Report 2014. IARC Publications; Lyon, France: 2015
|
|
8
|
Paydas S, Acikalin A, Ergin M, Celik H,
Yavuz B and Tanriverdi K: Micro-RNA (miRNA) profile in Hodgkin
lymphoma: Association between clinical and pathological variables.
Med Oncol. 33:342016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Healy NA, Heneghan HM, Miller N, Osborne
CK, Schiff R and Kerin MJ: Systemic mirnas as potential biomarkers
for malignancy. Int J Cancer. 131:2215–2222. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Musilova K and Mraz M: MicroRNAs in B-cell
lymphomas: How a complex biology gets more complex. Leukemia.
29:1004–1017. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zheng Y, Yin L, Chen H, Yang S, Pan C, Lu
S, Miao M and Jiao B: miR-376a suppresses proliferation and induces
apoptosis in hepatocellular carcinoma. FEBS Lett. 586:2396–2403.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zehavi L, Avraham R, Barzilai A, Bar-Ilan
D, Navon R, Sidi Y, Avni D and Leibowitz-Amit R: Silencing of a
large microRNA cluster on human chromosome 14q32 in melanoma:
Biological effects of mir-376a and mir-376c on insulin growth
factor 1 receptor. Mol Cancer. 11:442012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Arribas AJ, Gómez-Abad C, Sánchez-Beato M,
Martinez N, Dilisio L, Casado F, Cruz MA, Algara P, Piris MA and
Mollejo M: Splenic marginal zone lymphoma: Comprehensive analysis
of gene expression and miRNA profiling. Mod Pathol. 26:889–901.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu X, Li Z and Liu J: MiRNAs in primary
cutaneous lymphomas. Cell Prolif. 48:271–277. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lawrie CH: MicroRNAs and lymphomagenesis:
A functional review. Br J Haematol. 160:571–581. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Swerdlow SH, Campo E, Pileri SA, Harris
NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz
AD and Jaffe ES: The 2016 revision of the World Health Organization
classification of lymphoid neoplasms. Blood. 127:2375–2390. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sicinski P, Donaher JL, Geng Y, Parker SB,
Gardner H, Park MY, Robker RL, Richards JS, McGinnis LK, Biggers
JD, et al: Cyclin D2 is an FSH-responsive gene involved in gonadal
cell proliferation and oncogenesis. Nature. 384:470–474. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Heneghan HM, Miller N, Lowery AJ, Sweeney
KJ, Newell J and Kerin MJ: Circulating microRNAs as novel minimally
invasive biomarkers for breast cancer. Ann Surg. 251:499–505. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang J, Chen J, Chang P, LeBlanc A, Li D,
Abbruzzesse JL, Frazier ML, Killary AM and Sen S: MicroRNAs in
plasma of pancreatic ductal adenocarcinoma patients as novel
blood-based biomarkers of disease. Cancer Prev Res (Phila).
2:807–813. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Ann Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang L, Volinia S, Bonome T, Calin GA,
Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K,
et al: Genomic and epigenetic alterations deregulate microRNA
expression in human epithelial ovarian cancer. Proc Natl Acad Sci
USA. 105:7004–7009. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Diaz-Moralli S, Tarrado-Castellarnau M,
Miranda A and Cascante M: Targeting cell cycle regulation in cancer
therapy. Pharmacol Ther. 138:255–271. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stewart ZA, Westfall MD and Pietenpol JA:
Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol
Sci. 24:139–145. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cordon-Cardo C: Mutations of cell cycle
regulators. Biological and clinical implications for human
neoplasia. Am J Pathol. 147:545–560. 1995.PubMed/NCBI
|
|
27
|
Hunter T and Pines J: Cyclins and cancer
II: Cyclin D and CDK inhibitors come of age. Cell. 79:573–582.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bartkova J, Lukas J, Strauss M and Bartek
J: The PRAD-1/cyclin D1 oncogene product accumulates aberrantly in
a subset of colorectal carcinomas. Int J Cancer. 58:568–573. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Motokura T and Arnold A: Cyclins and
oncogenesis. Biochim Biophys Acta. 1155:63–78. 1993.PubMed/NCBI
|
|
30
|
Surhone LM, Tennoe MT, Henssonow SF,
Macromolecule and Acid N: Cyclin D2. 2011.
|
|
31
|
Thompson CB: Apoptosis in the pathogenesis
and treatment of disease. Science. 267:1456–1462. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fuchs Y and Steller H: Programmed cell
death in animal development and disease. Cell. 147:742–758. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Youle RJ and Strasser A: The BCL-2 protein
family: Opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tsui D, Vessey JP, Tomita H, Kaplan DR and
Miller FD: FoxP2 regulates neurogenesis during embryonic cortical
development. J Neurosci. 33:244–258. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vernes SC, Oliver PL, Spiteri E, Lockstone
HE, Puliyadi R, Taylor JM, Ho J, Mombereau C, Brewer A, Lowy E, et
al: Foxp2 regulates gene networks implicated in neurite outgrowth
in the developing brain. PLoS Genetics. 7:e10021452011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Taylor BS, Schultz N, Hieronymus H,
Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva
B, et al: Integrative genomic profiling of human prostate cancer.
Cancer Cell. 18:11–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bignone PA and Banham AH: FOXP3+
regulatory T cells as biomarkers in human malignancies. Expert Opin
Biol Ther. 8:1897–1920. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Teufel A, Wong EA, Mukhopadhyay M, Malik N
and Westphal H: FoxP4, a novel forkhead transcription factor.
Biochim Biophys Acta. 1627:147–152. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Campbell AJ, Lyne L, Brown PJ, Launchbury
RJ, Bignone P, Chi J, Roncador G, Lawrie CH, Gatter KC, Kusec R and
Banham AH: Aberrant expression of the neuronal transcription factor
FOXP2 in neoplastic plasma cells. Br J Haematol. 149:221–230. 2010.
View Article : Google Scholar : PubMed/NCBI
|
